Close Menu

NEW YORK – Twist Bioscience said Tuesday after the close of the market that it intends to sell up to $100 million of its common stock in an underwritten public offering.

Twist said it plans to use the proceeds to invest in its research and development organization, including pharmaceutical biologics drug discovery and DNA data storage; to scale its next-generation sequencing commercial operations; and to expand its production capacity. The company will also use the funds for working capital and general corporate purposes. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.